Adult Mesenchymal Tumour Medical Therapy Unit, Cancer Medicine Department, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy.
Chordoma Foundation, Durham, USA.
Lancet Oncol. 2015 Feb;16(2):e71-83. doi: 10.1016/S1470-2045(14)71190-8.
Chordomas are very rare bone malignant tumours that have had a shortage of effective treatments for a long time. New treatments are now available for both the local and the metastatic phase of the disease, but the degree of uncertainty in selecting the most appropriate treatment remains high and their adoption remains inconsistent across the world, resulting in suboptimum outcomes for many patients. In December, 2013, the European Society for Medical Oncology (ESMO) convened a consensus meeting to update its clinical practice guidelines on sarcomas. ESMO also hosted a parallel consensus meeting on chordoma that included more than 40 chordoma experts from several disciplines and from both sides of the Atlantic, with the contribution and sponsorship of the Chordoma Foundation, a global patient advocacy group. The consensus reached at that meeting is shown in this position paper.
脊索瘤是一种非常罕见的骨恶性肿瘤，长期以来缺乏有效的治疗方法。目前，这种疾病的局部和转移阶段都有新的治疗方法，但在选择最合适的治疗方法时，仍存在高度的不确定性，而且在全球范围内，这些治疗方法的应用并不一致，导致许多患者的治疗效果不理想。2013 年 12 月，欧洲肿瘤内科学会（ESMO）召开了一次共识会议，更新其肉瘤临床实践指南。ESMO 还主办了一次关于脊索瘤的平行共识会议，该会议邀请了来自大西洋两岸多个学科的 40 多名脊索瘤专家，并有脊索瘤基金会（一个全球性的患者权益组织）的参与和赞助。本次会议达成的共识在这份立场文件中列出。
